Product Name,Generic Name,Manufacturer,NDC Code,Therapeutic Area,Indication,Number of Doses,WAC Price (USD),Government Price (340B/VA),Commercial Insurance Price,PAP Available,Prior Authorization Required,Treatment Journey Phase 1 - Pre-Infusion,Treatment Journey Phase 2 - Manufacturing,Treatment Journey Phase 3 - Infusion,Treatment Journey Phase 4 - Post-Infusion,Days from Enrollment to Infusion,Insurance Coverage Types,Copay Assistance Program,REMS Program Required,Specialty Pharmacy Required,Inpatient vs Outpatient
Kymriah,tisagenlecleucel,Novartis,0078-0813-93,CAR-T Therapy,Pediatric/Young Adult ALL,"Single dose, patient-specific","$475,000","$285,000 (340B discounted)","Varies by plan, typically $400,000-475,000",Yes - Novartis Patient Assistance,Yes - Medical and Pharmacy PA,"Screening: HLA typing not required, disease assessment, leukapheresis eligibility evaluation, patient education (Days 1-7); Leukapheresis: T-cell collection at qualified center, cryopreservation (Day 7-10); Bridging therapy: Optional chemotherapy during manufacturing if needed (Days 10-35)","Manufacturing at Novartis facility: 3-4 weeks typical, T-cell activation, genetic modification with lentiviral vector, expansion, quality testing, cryopreservation, shipment to treatment center (Days 10-35)","Lymphodepleting chemotherapy: Fludarabine 25mg/m2 + Cyclophosphamide 250-500mg/m2 for 3 days (Days 35-37); Day 0: Kymriah infusion over 20-30 minutes, admit to hospital minimum 7 days for CRS/neurotoxicity monitoring, tocilizumab available bedside","Hospital monitoring 7-10 days: Daily neurological assessments, cytokine monitoring, CRS management (tocilizumab, steroids if needed); Outpatient monitoring: Weekly visits x 4 weeks, then monthly x 4 months; Long-term: Every 3 months for 5 years minimum; Monitoring for B-cell aplasia, immunoglobulin replacement as needed",35-45 days average,"Medicare Part B (buy-and-bill), Commercial insurance, Medicaid, VA/DoD, 340B eligible",Yes - Novartis Oncology Patient Assistance,No specific REMS but Risk Evaluation required,Yes - specialty pharmacy coordinates,Inpatient required for infusion and monitoring
Yescarta,axicabtagene ciloleucel,Gilead Sciences/Kite Pharma,68180-0151-01,CAR-T Therapy,Large B-Cell Lymphoma,"Single dose, patient-specific","$373,000","$223,800 (340B discounted)","Varies by plan, typically $330,000-373,000",Yes - Kite Konnect Patient Support,Yes - Medical and Pharmacy PA,"Screening: Disease staging (PET/CT), leukapheresis eligibility, bridging therapy planning (Days 1-7); Leukapheresis: T-cell collection, must collect adequate cells, cryopreservation (Days 7-10); Bridging: Chemotherapy or radiation for disease control during manufacturing (Days 10-28)","Manufacturing at Kite facility: 2-3 weeks typical, T-cell activation, retroviral transduction with anti-CD19 CAR, expansion, quality release testing, cryopreservation and shipping (Days 10-28)","Lymphodepletion: Cyclophosphamide 500mg/m2 + Fludarabine 30mg/m2 for 3 days (Days 26-28); Day 0: Yescarta infusion over 30 minutes, minimum 7 days inpatient monitoring for CRS/ICANS, tocilizumab and emergency medications at bedside","Inpatient: 7-14 days for CRS/neurotoxicity monitoring, daily neurological exams, cytokine panels; Outpatient: Week 1 and 2 post-discharge visit, then monthly x 3 months; Long-term: Every 3 months for Year 1, then every 6 months; B-cell monitoring, IVIG replacement therapy",28-38 days average,"Medicare Part B, Commercial, Medicaid, VA/340B",Yes - Kite Konnect Copay Program,Yes - Yescarta REMS program,Yes - specialty distribution,Inpatient required minimum 7 days
Breyanzi,lisocabtagene maraleucel,Bristol Myers Squibb/Juno,0003-2550-11,CAR-T Therapy,Large B-Cell Lymphoma,"Single dose, patient-specific","$410,300","$246,180 (340B discounted)","Varies by plan, typically $370,000-410,000",Yes - BMS Access Support,Yes - Medical and Pharmacy PA,"Screening: Staging scans, organ function tests, leukapheresis planning (Days 1-5); Leukapheresis: T-cell collection with CD4/CD8 selection, cryopreservation (Days 5-8); Bridging therapy: Disease management during manufacturing period (Days 8-30)","Manufacturing at Juno/BMS facility: 2-4 weeks, separate CD4+ and CD8+ CAR-T production, lentiviral transduction, defined 1:1 CD4:CD8 ratio, expansion and release testing (Days 8-30)","Lymphodepletion: Cyclophosphamide 300mg/m2 + Fludarabine 30mg/m2 for 3 days (Days 28-30); Day 0: Breyanzi infusion of CD4+ then CD8+ components, hospitalization 7-10 days minimum for monitoring, CRS/ICANS management protocols","Hospital stay: 7-10 days with neurological monitoring every 4-6 hours, CRS grading, tocilizumab/steroids as needed; Outpatient: Weekly x 4 weeks then biweekly x 2 months; Long-term surveillance: Every 3 months Year 1, then every 6 months; Immunoglobulin monitoring",30-40 days average,"Medicare Part B, Commercial insurance, Medicaid, 340B/VA",Yes - BMS Access Support Copay,Yes - Breyanzi REMS program,Yes - specialty pharmacy network,Inpatient required for infusion period
Abecma,idecabtagene vicleucel,Bristol Myers Squibb/Bluebird Bio,0003-3158-11,CAR-T Therapy,Relapsed/Refractory Multiple Myeloma,"Single dose, patient-specific","$419,500","$251,700 (340B discounted)","Varies by plan, typically $380,000-420,000",Yes - BMS Patient Assistance,Yes - Medical and Pharmacy PA,"Screening: Multiple myeloma disease assessment, BCMA expression confirmation, bridging therapy planning (Days 1-7); Leukapheresis: T-cell collection at certified center (Days 7-10); Bridging: Anti-myeloma therapy during manufacturing to control disease (Days 10-37)","Manufacturing: 4-6 weeks typical, T-cell activation, lentiviral vector transduction with anti-BCMA CAR, expansion, quality control testing, cryopreservation, shipping to site (Days 10-42)","Lymphodepletion: Cyclophosphamide 300mg/m2 + Fludarabine 30mg/m2 for 3 days (Days 40-42); Day 0: Abecma infusion over 30-60 minutes, minimum 7 days hospitalization, CRS/neurotoxicity monitoring, supportive care medications available","Hospital monitoring: 7-10 days for CRS (peaks Day 1-7) and neurotoxicity monitoring; Outpatient: Weekly visits x 4 weeks, biweekly x 2 months; Long-term: Monthly visits for 4 months, then every 3 months; Monitor for hypogammaglobulinemia, cytopenias; IVIG replacement as needed",42-52 days average,"Medicare Part B, Commercial insurance, Medicaid, VA/340B",Yes - BMS Access Support,Yes - Abecma REMS program,Yes - specialty distribution required,Inpatient required minimum 7 days
Tecartus,brexucabtagene autoleucel,Gilead Sciences/Kite Pharma,68180-0152-01,CAR-T Therapy,Mantle Cell Lymphoma,"Single dose, patient-specific","$373,000","$223,800 (340B discounted)","Varies by plan, typically $330,000-373,000",Yes - Kite Konnect Support,Yes - Medical and Pharmacy PA,"Screening: Disease restaging, CNS assessment, leukapheresis eligibility (Days 1-7); Leukapheresis: Mononuclear cell collection, adequate T-cell numbers required (Days 7-10); Bridging: Chemotherapy to control aggressive MCL during manufacturing (Days 10-28)","Manufacturing at Kite: 2-3 weeks, T-cell enrichment, retroviral transduction with CD19 CAR, expansion, testing for sterility/potency/identity, cryopreservation (Days 10-28)","Lymphodepletion: Cyclophosphamide 500mg/m2 + Fludarabine 30mg/m2 x 3 days (Days 26-28); Day 0: Tecartus infusion, admit minimum 7 days for CRS/ICANS monitoring, emergency medications at bedside including tocilizumab","Inpatient: 7-14 days monitoring for CRS (median onset Day 2) and neurotoxicity (median Day 6-7), supportive care; Outpatient: Weekly x 2-4 weeks, then monthly x 3 months; Long-term: Every 3 months Year 1; Monitor B-cells, immunoglobulins",28-38 days average,"Medicare Part B, Commercial, Medicaid, 340B/VA",Yes - Kite Konnect Copay,Yes - Tecartus REMS program,Yes - specialty pharmacy,Inpatient required minimum 7 days
Carvykti,ciltacabtagene autoleucel,Janssen/Legend Biotech,57894-0150-01,CAR-T Therapy,Relapsed/Refractory Multiple Myeloma,"Single dose, patient-specific","$465,000","$279,000 (340B discounted)","Varies by plan, typically $420,000-465,000",Yes - Janssen CarePath,Yes - Medical and Pharmacy PA,"Screening: Myeloma disease assessment, prior BCMA therapy evaluation, organ function (Days 1-7); Leukapheresis: T-cell collection at authorized site, adequate cell count verification (Days 7-10); Bridging: Anti-myeloma therapy during 5-6 week manufacturing (Days 10-45)","Manufacturing: 5-6 weeks at Legend/Janssen facility, T-cell selection and activation, lentiviral transduction with dual BCMA-targeting CAR, expansion, release testing, shipping (Days 10-45)","Lymphodepletion: Cyclophosphamide 300mg/m2 + Fludarabine 30mg/m2 x 3 days (Days 43-45); Day 0: Carvykti infusion, hospitalization minimum 7-10 days, CRS/ICANS/Parkinsonism monitoring, tocilizumab/steroids available","Hospital stay: 7-14 days for toxicity monitoring including movement disorders; Outpatient: Weekly x 4 weeks, then biweekly x 8 weeks; Long-term: Monthly x 6 months, then every 3 months; Monitor for delayed neurotoxicity, cytopenias, infections; IVIG as needed",45-55 days average,"Medicare Part B, Commercial insurance, Medicaid, VA/340B",Yes - Janssen CarePath Savings,Yes - Carvykti REMS program,Yes - specialty distribution,Inpatient required 7-14 days
Lyfgenia,betibeglogene autotemcel,Bluebird Bio,71074-0155-01,Gene Therapy,Sickle Cell Disease (age 12+),"Single dose, one-time treatment","$3,100,000","$1,860,000 (340B rate)","Varies, typically $2,800,000-3,100,000",Yes - Bluebird Bio Patient Support,Yes - Prior Authorization required,"Screening: Sickle cell genotype confirmation, organ function assessment, fertility preservation counseling (Days 1-14); Mobilization: Plerixafor for stem cell mobilization (Days 14-16); Apheresis: CD34+ stem cell collection, adequate cell dose verification (Days 16-18)","Manufacturing: 4-6 months, CD34+ cell transduction with BB305 lentiviral vector containing modified beta-globin gene, cell expansion, extensive release testing for replication-competent lentivirus (Days 18-180)","Myeloablative conditioning: Busulfan 3.2mg/kg/day IV x 4 days for full myeloablation (Days 176-179); Day 0: Lyfgenia infusion of gene-modified cells, hospitalization 4-6 weeks for engraftment, monitor for VOC, infections, mucositis, support with transfusions","Hospital stay: 4-6 weeks for neutrophil and platelet engraftment; Early follow-up: Weekly x 4 weeks post-discharge; Intermediate: Monthly x 12 months; Long-term: Every 3 months for Year 2-5, then annually up to 15 years for gene therapy safety monitoring per FDA",180-200 days average,"Medicare Part B (limited), Commercial insurance with case management, Medicaid varies by state",Yes - Bluebird Bio Financial Support,No specific REMS but Long-term Follow-up required,Yes - specialty cell therapy coordination,Inpatient required 4-6 weeks
Zynteglo,betibeglogene autotemcel,Bluebird Bio,71074-0150-01,Gene Therapy,Transfusion-Dependent Beta-Thalassemia,"Single dose, one-time treatment","$2,800,000","$1,680,000 (340B rate)","Varies, typically $2,500,000-2,800,000",Yes - Bluebird Bio Patient Access,Yes - Prior Authorization required,"Screening: Beta-thalassemia genotype, transfusion history, iron overload assessment, fertility counseling (Days 1-14); Mobilization: Plerixafor stem cell mobilization (Days 14-16); Apheresis: CD34+ hematopoietic stem cell collection (Days 16-18)","Manufacturing: 4-6 months, transduction of CD34+ cells with BB305 lentiviral vector (beta-globin gene), expansion, testing for vector copy number and replication-competent lentivirus (Days 18-180)","Myeloablative conditioning: Busulfan IV 3.2mg/kg/day x 4 days (Days 176-179); Day 0: Zynteglo infusion, hospitalization for engraftment 4-6 weeks, monitor for infections, VOC if present, mucositis management, transfusion support during aplasia","Hospital stay: 4-6 weeks for hematopoietic recovery; Post-discharge: Weekly x 4-8 weeks, then monthly x 12 months; Long-term: Every 3 months Years 2-5, then annually for up to 15 years; Monitor hemoglobin, transfusion independence, vector integration",180-200 days average,"Medicare (limited coverage), Commercial with high complexity case management, Some state Medicaid",Yes - Bluebird Bio Patient Support,No REMS but 15-year registry,Yes - specialty gene therapy coordination,Inpatient 4-6 weeks required
Casgevy,exagamglogene autotemcel,Vertex/CRISPR Therapeutics,74115-0001-01,CRISPR Gene Therapy,Sickle Cell Disease and Beta-Thalassemia,"Single dose, one-time treatment","$2,200,000","$1,320,000 (340B)","Varies, typically $2,000,000-2,200,000",Yes - Vertex Patient Support,Yes - Prior Authorization required,"Screening: Genetic confirmation SCD or TDT, comprehensive evaluation, fertility preservation (Days 1-21); Mobilization: Plerixafor subcutaneous for stem cell mobilization (Days 21-23); Apheresis: CD34+ stem cell collection, cell count verification (Days 23-25)","Manufacturing: 4-6 months, CRISPR/Cas9 editing of BCL11A gene in CD34+ cells to reactivate fetal hemoglobin production, extensive quality testing, characterization of editing efficiency (Days 25-180)","Myeloablative conditioning: Busulfan IV pharmacokinetically dosed x 4 days (Days 176-179); Day 0: Casgevy infusion of CRISPR-edited cells, hospitalization minimum 4-6 weeks for engraftment, antimicrobial prophylaxis, transfusion support","Hospital: 4-6 weeks for neutrophil/platelet recovery, monitor for infections, VOC events; Outpatient: Weekly x 4 weeks, biweekly x 4 weeks, then monthly x 12 months; Long-term: Every 3 months Years 2-5, annually to Year 15; Fetal hemoglobin levels, editing efficiency monitoring",180-200 days from start,"Medicare evaluation ongoing, Commercial insurance, Medicaid state-dependent",Yes - Vertex Support Program,No REMS but 15-year registry required,Yes - specialty gene therapy sites only,Inpatient required 4-6 weeks minimum
Zolgensma,onasemnogene abeparvovec,Novartis Gene Therapies,0078-0850-01,Gene Therapy,Spinal Muscular Atrophy Type 1,"Single dose, one-time IV infusion","$2,125,000","$1,275,000 (340B)","Varies, typically $1,900,000-2,125,000",Yes - Novartis Gene Therapies Patient Assistance,Yes - Prior Authorization required,"Screening: SMN1/SMN2 genetic testing confirmation, anti-AAV9 antibody testing (exclusion if high titer), liver function, cardiac function assessment, pre-medication planning (Days 1-14)","Not applicable - Zolgensma is manufactured product, not patient-specific; Delivered directly to treatment site; Cold chain logistics critical","Pre-medication: Prednisolone 1mg/kg/day starting 1 day before infusion; Day 0: Zolgensma IV infusion over 60 minutes (dose based on weight), typically outpatient infusion at specialized center, monitoring for hypersensitivity","Post-infusion monitoring: Liver enzymes weekly x 3 months (hepatotoxicity monitoring), adjust steroid taper based on transaminases; Monthly assessment x 12 months; Long-term follow-up: Every 6 months to assess motor milestones, safety monitoring for 15 years per FDA",14-21 days from screening,"Medicare Part B, Commercial insurance (typically approved), Medicaid state-specific",Yes - Novartis Gene Therapies Support,No REMS but Risk Evaluation required,Yes - specialty infusion centers,Outpatient infusion at certified center
Roctavian,valoctocogene roxaparvovec,BioMarin Pharmaceutical,71843-0001-01,Gene Therapy,Severe Hemophilia A,"Single dose, one-time IV infusion","$2,900,000","$1,740,000 (340B)","Varies, typically $2,600,000-2,900,000",Yes - BioMarin RareConnections,Yes - Prior Authorization required,"Screening: Hemophilia A diagnosis confirmation (Factor VIII <1 IU/dL), anti-AAV5 antibody testing (exclusion criteria if positive), liver function tests, HIV status, hepatitis screening (Days 1-21)","Not applicable - manufactured product; AAV5 vector containing Factor VIII gene; Cold chain maintained during delivery to hemophilia treatment center","Pre-medication: Prednisolone 60mg daily starting 1 day before infusion; Day 0: Roctavian single IV infusion over 1-2 hours at hemophilia treatment center, monitor for infusion reactions, typically outpatient procedure","Post-infusion: Prednisolone taper over 60-90 days based on liver enzymes; Factor VIII levels checked weekly x 12 weeks, then monthly; Liver enzymes monitored weekly x 16 weeks; Long-term: Every 3 months Year 1, then every 6 months; Continue monitoring for immunosuppression duration; Annual evaluations for 15 years",21-28 days from screening,"Medicare Part B, Commercial insurance, Hemophilia Treatment Center funding, State programs",Yes - BioMarin RareConnections Assist,No REMS but long-term registry,Yes - hemophilia treatment centers only,Outpatient infusion at HTC
Luxturna,voretigene neparvovec,Spark Therapeutics/Roche,72501-0001-01,Gene Therapy,Inherited Retinal Disease (RPE65 mutation),"One-time, bilateral subretinal injection (one eye at a time)","$850,000 ($425,000 per eye)","$510,000 (340B) for both eyes","Varies, typically $750,000-850,000 total",Yes - Spark Therapeutics Patient Services,Yes - Prior Authorization required,"Screening: RPE65 mutation confirmation, retinal function testing, visual field assessment, sufficient viable retinal cells (Days 1-30); Surgical planning: Ophthalmology evaluation, anesthesia clearance, immunosuppression planning","Not applicable - manufactured AAV2 vector product with RPE65 gene; Delivered to surgical center in frozen state; Thawed prior to administration","Pre-procedure: Prednisolone 1mg/kg (max 40mg) starting 3 days before surgery; Day 0: Subretinal injection under general anesthesia (vitrectomy approach), one eye treated; Recovery: Outpatient same day typically; Second eye: Treated 6-18 days after first eye with same protocol","Post-procedure monitoring: Eye exams at Day 1, Week 1, Week 2, Month 1, Month 3, Month 6; Continue prednisolone taper over 2 weeks; Vision testing and retinal assessments; Long-term: Annual eye exams, vision monitoring; Immunosuppression typically 1-2 weeks per eye",30-60 days total (including both eyes),"Medicare Part B, Commercial insurance, Medicaid (varies by state), Foundation grants",Yes - Spark Therapeutics Support,No REMS,Yes - specialized ophthalmology centers,Outpatient surgical procedure
Ocrevus,ocrelizumab,Genentech/Roche,50242-0135-01,Multiple Sclerosis,Relapsing MS and Primary Progressive MS,IV infusion every 6 months,"$65,000/year ($32,500 per infusion)","$39,000/year (340B discount)","Varies by plan, typically $58,000-65,000/year",Yes - Genentech Patient Foundation,Yes - Prior Authorization required for most payers,"Pre-infusion screening: JC virus testing, hepatitis B screening, immunoglobulin levels, complete blood count, vaccination status review; Patient education on infusion reactions and PML risk; Schedule infusion appointment","Not applicable - commercially manufactured monoclonal antibody","Initial dosing: 300mg IV infusion (given as two 150mg infusions 2 weeks apart); Pre-medication with methylprednisolone 100mg IV, antihistamine, acetaminophen 30-60 minutes before infusion; Infusion over 2.5-3 hours for first dose, 2 hours for subsequent; Monitor for infusion reactions during and 1 hour post-infusion","Maintenance: 600mg IV every 6 months; Monitor for infusion reactions, infections, immunoglobulin levels every 6 months; Annual MRI brain; Vaccinations: Live vaccines contraindicated; PML monitoring: Any new neurological symptoms require urgent evaluation; B-cell monitoring",Initial infusion visit, then every 6 months ongoing,"Medicare Part B, Commercial insurance, Medicaid (varies), Specialty pharmacy",Yes - Genentech Copay Card up to $15,000/year,No REMS but Risk Evaluation,Yes - specialty infusion pharmacy,Outpatient infusion center
Kesimpta,ofatumumab,Novartis,0078-0882-61,Multiple Sclerosis,Relapsing MS,Self-injection once monthly,"$88,000/year","$52,800/year (340B)","Varies, typically $75,000-88,000/year",Yes - Novartis Patient Assistance,Yes - Prior Authorization required,"Pre-treatment screening: Hepatitis B screening, live vaccine administration (at least 4 weeks before starting), baseline MRI; Patient training on self-injection technique using Sensoready pen","Not applicable - manufactured monoclonal antibody in pre-filled pen","Initial loading doses: Week 0, 1, and 2 (20mg subcutaneous); Weeks 4 and beyond: 20mg subcutaneous once monthly; Self-administered at home with Sensoready autoinjector; Pre-medication not typically required; Injection site reactions common initially","Monthly self-injection at home; Monitor for infections, immunoglobulin levels every 6-12 months; Annual MRI; Hepatitis B reactivation monitoring if risk factors; PML surveillance: Report any new neurological symptoms; Live vaccines contraindicated during treatment; Pneumococcal vaccine recommended",Can start within 1-2 weeks of screening,"Medicare Part D, Commercial insurance, Medicaid (state-dependent), Specialty pharmacy",Yes - Novartis Copay Program,No REMS,Yes - specialty pharmacy dispenses,Self-administered at home (subcutaneous)
Tysabri,natalizumab,Biogen,59075-0730-15,Multiple Sclerosis,Relapsing MS,IV infusion every 4 weeks,"$78,000/year","$46,800/year (340B)","Varies, typically $70,000-78,000/year",Yes - Biogen Support Services,Yes - Prior Authorization required,"Pre-treatment: JC virus antibody testing (critical for PML risk stratification), MRI brain with gadolinium baseline; TOUCH program enrollment (prescriber, patient, infusion center); Patient education on PML risk; Liver function tests","Not applicable - manufactured humanized monoclonal antibody","Infusion: 300mg IV over 1 hour every 4 weeks; No pre-medication typically required; Monitor during infusion and 1 hour post-infusion for hypersensitivity; Must be administered at TOUCH-certified infusion center","Monthly infusions; JC virus antibody testing every 6 months if negative, every 3 months if positive; MRI brain every 6-12 months; PML surveillance: High index of suspicion for any neurological changes; TOUCH program ongoing monitoring; Liver enzyme monitoring periodically",Can start within 1-2 weeks of TOUCH enrollment,"Medicare Part B, Commercial insurance, Medicaid varies, Specialty infusion",Yes - Biogen Copay Program,Yes - TOUCH REMS program mandatory,Yes - TOUCH certified sites only,Outpatient infusion at TOUCH site
Mavenclad,cladribine,EMD Serono,44087-1201-01,Multiple Sclerosis,Relapsing MS,"Two treatment courses (Year 1 and 2), oral tablets","$108,000 for both years","$64,800 (340B) total","Varies, typically $95,000-108,000 total",Yes - EMD Serono Patient Support,Yes - Prior Authorization required,"Pre-treatment: Tuberculosis screening, hepatitis screening, HIV test, complete blood count with differential, pregnancy test (required), baseline MRI; Patient must have active MS and lymphocyte count ≥800 cells/μL; REMS program enrollment","Not applicable - oral tablets manufactured and distributed through specialty pharmacy; Calculated dosing based on body weight","Year 1: One treatment course - typically 10mg or 20mg tablets daily for 4-5 days in Month 1, then repeat in Month 2; Patient takes tablets at home; Year 2: Second treatment course with same dosing schedule in Months 1 and 2; No treatment in Years 3 and 4 (drug effect persists)","Post-treatment monitoring: Complete blood count at 2 and 6 months after each treatment course; MRI annually; Tuberculosis monitoring; Herpes prophylaxis (acyclovir or valacyclovir) during treatment and 2 months after; Live vaccines contraindicated; Pregnancy prevention mandatory (2 forms contraception)",Can start within 2-4 weeks of screening,"Medicare Part D, Commercial insurance, Medicaid (state-dependent), Specialty pharmacy",Yes - EMD Serono Copay Assistance,Yes - Mavenclad REMS (pregnancy prevention),Yes - specialty pharmacy required,Oral medication taken at home
Zeposia,ozanimod,Bristol Myers Squibb,0003-0264-11,Multiple Sclerosis,Relapsing MS,Oral daily capsule,"$98,000/year","$58,800/year (340B)","Varies, typically $85,000-98,000/year",Yes - BMS Access Support,Yes - Prior Authorization required,"Pre-treatment: Cardiac evaluation (ECG, assess for heart block), ophthalmic exam (macular edema screening), complete blood count, liver function tests, hepatitis B/C screening, varicella immunity confirmation; Recent cardiovascular events are contraindications","Not applicable - oral sphingosine-1-phosphate receptor modulator; Manufactured and distributed through specialty pharmacy","Dose escalation: Days 1-4 ozanimod 0.23mg, Days 5-7 ozanimod 0.46mg, Day 8 onwards 0.92mg daily; Escalation reduces cardiac effects; First dose observation not required (unlike fingolimod); Take once daily with or without food; Maintenance: 0.92mg daily continuously","Continue daily dosing; Monitor: Complete blood count every 3 months first year; Liver enzymes periodically; Ophthalmic exam at 3-4 months then as needed; Macular edema surveillance; MRI annually; Skin exams periodically (melanoma risk); Live vaccines: Wait 3 months after stopping before administering",Can start within 1-2 weeks of screening,"Medicare Part D, Commercial insurance, Medicaid (state-dependent), Specialty pharmacy",Yes - BMS Copay Savings Card,No REMS,Yes - specialty pharmacy dispenses,Oral medication taken at home
Mavacamten,mavacamten,Bristol Myers Squibb,0003-4850-11,Cardiology,Obstructive Hypertrophic Cardiomyopathy,Oral daily capsule,"$225,000/year","$135,000/year (340B)","Varies by plan, typically $200,000-225,000/year",Yes - BMS Patient Assistance,Yes - Prior Authorization required,"Pre-treatment: Echocardiogram with LVEF assessment (must be ≥55%), LVOT gradient measurement, cardiac MRI if indicated, pregnancy test (teratogenic), contraception counseling; Mavacamten REMS enrollment required","Not applicable - oral cardiac myosin inhibitor; Distributed only through certified specialty pharmacies enrolled in REMS program","Starting dose: 5mg once daily; Dose adjustments: Echocardiogram at Week 4, 8, 12, then every 12 weeks; Adjust dose (2.5mg, 5mg, 10mg, 15mg) based on LVEF and LVOT gradient; If LVEF <50%, interrupt therapy; Take with or without food same time daily","Ongoing monitoring: Echocardiograms every 12 weeks during maintenance for LVEF and LVOT gradient assessment; Interrupt if LVEF drops below 50%; Drug interactions: Avoid strong/moderate CYP2C19 inhibitors; Pregnancy prevention mandatory (REMS); Continue therapy as long as beneficial and LVEF maintained",Can start within 1-2 weeks of REMS enrollment,"Medicare Part D, Commercial insurance, Specialty cardiology programs",Yes - BMS Copay Support Program,Yes - Mavacamten REMS (pregnancy prevention),Yes - REMS certified specialty pharmacy only,Oral medication at home with echo monitoring
Tafamidis,tafamidis meglumine or free acid,Pfizer,0069-0222-30 (Vyndaqel) / 0069-0232-30 (Vyndamax),Cardiology,Transthyretin Amyloid Cardiomyopathy,Oral daily capsule,"$225,000/year","$135,000/year (340B)","Varies, typically $200,000-225,000/year",Yes - Pfizer Patient Assistance,Yes - Prior Authorization required,"Pre-treatment: Confirm ATTR-CM diagnosis (cardiac biopsy, technetium scan, or genetic testing for hereditary ATTR); Echocardiogram, NT-proBNP, 6-minute walk test, functional class assessment; Biomarker panel baseline","Not applicable - oral TTR stabilizer; Vyndamax (tafamidis 61mg) or Vyndaqel (tafamidis meglumine 80mg - 4 capsules) are therapeutically equivalent","Dosing: Vyndamax 61mg once daily OR Vyndaqel 80mg (four 20mg capsules) once daily; Take consistently same time each day; Can take with or without food; No dose adjustments for renal or hepatic impairment; Continue indefinitely","Ongoing monitoring: Echocardiograms every 6-12 months, NT-proBNP every 3-6 months, 6-minute walk test every 6 months; Functional assessment; Monitor for disease progression; Generally well-tolerated with minimal side effects; Annual comprehensive cardiovascular assessment",Can start within 1-2 weeks of diagnosis confirmation,"Medicare Part D (high cost sharing), Commercial insurance, Specialty pharmacy",Yes - Pfizer Savings Program,No REMS,Yes - specialty pharmacy required,Oral medication taken at home
Entresto,sacubitril/valsartan,Novartis,0078-0699-15,Cardiology,Heart Failure with Reduced Ejection Fraction,Oral twice daily tablet,"$6,600/year","$3,960/year (340B)","Varies, typically $5,500-6,600/year",Yes - Novartis Patient Assistance,Yes - Prior Authorization required for most plans,"Pre-treatment: Baseline blood pressure, renal function, potassium level; Must discontinue ACE inhibitor at least 36 hours before starting (angioedema risk); Assess for history of angioedema","Not applicable - oral ARNI (angiotensin receptor-neprilysin inhibitor); Widely available through retail and specialty pharmacy","Starting dose: Typically 49mg/51mg twice daily (or 24mg/26mg if dose-sensitive); Target dose: 97mg/103mg twice daily; Titrate every 2-4 weeks as tolerated based on BP and renal function; Take with or without food","Ongoing monitoring: Blood pressure, renal function, and potassium within 1-2 weeks of initiation and dose changes; Monitor for hypotension, hyperkalemia, renal dysfunction; Continue indefinitely for heart failure management; Regular cardiology follow-up",Can start immediately after ACE-I washout (36 hours),"Medicare Part D, Commercial insurance, Medicaid, Retail and specialty pharmacy",Yes - Novartis Copay Card,No REMS,No - retail pharmacy available,Oral medication at home
Pluvicto,lutetium-177 PSMA-617,Novartis/Advanced Accelerator Applications,71195-0001-01,Radioligand Therapy,Metastatic Castration-Resistant Prostate Cancer,"6 IV infusions, every 6 weeks","$42,500 per dose, $255,000 for full course","$25,500 per dose (340B), $153,000 full course","Varies, typically $230,000-255,000 for 6 doses",Yes - Novartis Patient Assistance,Yes - Prior Authorization required,"Pre-treatment: PSMA-PET scan to confirm PSMA-positive disease, bone marrow function assessment (adequate platelets, hemoglobin, neutrophils), renal function (eGFR ≥30 mL/min), prior taxane chemotherapy required; Radiation safety counseling","Not applicable - Pluvicto is manufactured radioactive therapeutic; Shipped to authorized treatment centers with nuclear medicine capability; Cold chain and radiation safety protocols","Day 0: Pluvicto 7.4 GBq (200 mCi) IV infusion over 30 minutes; Pre-hydration and antiemetics; Post-infusion: Hydration for 3-4 hours, void frequently to reduce radiation exposure; Radiation safety precautions for 2-7 days; Repeat every 6 weeks x 6 doses total","Post-infusion monitoring: Same-day discharge typical with radiation safety instructions; Blood counts and renal function before each subsequent dose; PSMA-PET and CT imaging after doses 2-4 and at end of treatment; PSA monitoring; Toxicity assessment (myelosuppression, xerostomia, renal); Hold or discontinue if significant toxicity",6 weeks between doses, 36 weeks total treatment,"Medicare Part B, Commercial insurance, Medicaid (varies), Specialty nuclear medicine pharmacy",Yes - Novartis Copay Assistance,No REMS but Radiation Safety training,Yes - authorized nuclear medicine centers only,Outpatient infusion at nuclear medicine facility
Lutathera,lutetium-177 dotatate,Novartis/Advanced Accelerator Applications,71195-0002-01,Radioligand Therapy,Gastroenteropancreatic Neuroendocrine Tumors,"4 IV infusions, every 8 weeks","$54,000 per dose, $216,000 for full course","$32,400 per dose (340B), $129,600 full course","Varies, typically $195,000-216,000 for 4 doses",Yes - Novartis Patient Assistance,Yes - Prior Authorization required,"Pre-treatment: Somatostatin receptor imaging (OctreoScan or Gallium-68 DOTATATE PET) to confirm somatostatin receptor-positive disease; Adequate bone marrow, renal, hepatic function; Stop short-acting somatostatin analogs 24 hours before treatment, long-acting 4 weeks before","Not applicable - manufactured radioactive therapeutic targeting somatostatin receptors; Delivered to nuclear medicine centers with specialized handling","Day 0: Amino acid solution infusion 30 minutes before Lutathera for renal protection; Lutathera 7.4 GBq (200 mCi) IV over 30 minutes; Continue amino acid infusion during and 3 hours post-Lutathera; Antiemetics; Hydration; Radiation safety measures; Repeat every 8 weeks x 4 doses","Post-treatment: Radiation safety precautions 3-7 days; Monitor blood counts, renal function, liver function before each dose; Imaging (CT/MRI) after 2-3 doses and at completion; Monitor for myelosuppression, renal toxicity, hepatotoxicity; Hormone syndrome monitoring; Can resume somatostatin analogs if needed for symptoms",8 weeks between doses, 32 weeks total treatment,"Medicare Part B, Commercial insurance, NET specialty programs",Yes - Novartis Copay Program,No REMS but Radiation Safety protocols,Yes - authorized nuclear medicine facilities only,Outpatient infusion at nuclear medicine center
Blincyto,blinatumomab,Amgen,55513-0954-01,Bispecific Antibody,Acute Lymphoblastic Leukemia,Continuous IV infusion via pump,"$178,000 per treatment cycle","$106,800 (340B) per cycle","Varies, typically $160,000-178,000 per cycle",Yes - Amgen FIRST STEP,Yes - Prior Authorization required,"Pre-treatment: ALL diagnosis confirmation, minimal residual disease testing, neurological exam baseline, patient/caregiver training on infusion pump, central line placement if needed; Patient must not have active CNS leukemia","Not applicable - bispecific T-cell engager antibody manufactured by Amgen; Supplied as lyophilized powder for continuous IV infusion; Specialized infusion bags and pumps required","Cycle 1: Continuous IV infusion via pump over 28 days (starting dose 9 mcg/day days 1-7, then 28 mcg/day days 8-28); Hospitalized first 3-9 days for CRS/neurotoxicity monitoring; Pre-medication with dexamethasone; Patient/caregiver manages pump at home after initial monitoring; 14-day treatment-free interval between cycles","Ongoing cycles: Repeat 28-day infusions with 14-day breaks; Monitor for CRS, neurotoxicity (confusion, seizures), infections; Complete blood counts weekly; MRD assessment after Cycle 1; Continue up to 5 cycles for consolidation or until progression/toxicity; Neurological assessments; Pump site monitoring",28-day cycles with 14-day breaks, typically 3-5 cycles,"Medicare Part B, Commercial insurance, Medicaid, Specialty pharmacy",Yes - Amgen Safety Net Foundation,No REMS but Risk Evaluation and pump training,Yes - specialty infusion pharmacy and home health coordination,Initial inpatient then continuous home infusion
Tecvayli,teclistamab,Janssen,57894-0200-01,Bispecific Antibody,Relapsed/Refractory Multiple Myeloma,Subcutaneous injection weekly,"$22,000/month, ~$264,000/year","$13,200/month (340B), ~$158,000/year","Varies, typically $240,000-264,000/year",Yes - Janssen CarePath,Yes - Prior Authorization required,"Pre-treatment: Multiple myeloma assessment, step-up dosing preparation (hospitalization for first doses), IVIG baseline if low immunoglobulins, infection prophylaxis initiated; Patient education on CRS, ICANS, infections; Tocilizumab availability confirmed","Not applicable - bispecific antibody targeting BCMA and CD3; Manufactured by Janssen; Refrigerated storage required; Specialty pharmacy distribution","Step-up dosing: Day 1 0.06mg/kg SQ (hospitalized), Day 4 0.3mg/kg SQ (hospitalized minimum 24 hours), Day 7+ 1.5mg/kg SQ weekly (can be outpatient after step-up if no severe CRS/ICANS); Pre-medications for step-up doses; Monitor closely for CRS (peaks 1-3 days post-dose)","Weekly subcutaneous injections of 1.5mg/kg; Monitor for CRS, infections (IVIG replacement if needed), cytopenias; Complete blood counts before each dose initially, then less frequent; Can transition to every-other-week dosing after sustained response (≥6 months); Long-term infection monitoring, immunoglobulin levels",Step-up week 1, then weekly ongoing,"Medicare Part B, Commercial insurance, Medicaid, Specialty pharmacy",Yes - Janssen CarePath Savings Program,Yes - Tecvayli REMS program,Yes - specialty pharmacy and authorized sites,Inpatient for step-up, then outpatient weekly SQ
Talvey,talquetamab,Janssen,57894-0210-01,Bispecific Antibody,Relapsed/Refractory Multiple Myeloma,Subcutaneous injection weekly or every 2 weeks,"$20,000/month, ~$240,000/year","$12,000/month (340B), ~$144,000/year","Varies, typically $216,000-240,000/year",Yes - Janssen CarePath,Yes - Prior Authorization required,"Pre-treatment: Myeloma disease assessment, step-up dosing hospitalization planning, prophylaxis for infections, skin/nail care education (GPRC5D target expression on skin), taste changes anticipated; Tocilizumab availability; IVIG baseline","Not applicable - bispecific antibody targeting GPRC5D and CD3; Janssen manufactured; Requires refrigeration; Specialty pharmacy distribution","Step-up dosing: Day 1 0.01mg/kg SQ hospitalized, Day 4 0.04mg/kg SQ hospitalized minimum 48 hours, Day 7 0.4mg/kg SQ hospitalized/observed; Monitor for CRS/ICANS; Pre-medications (acetaminophen, antihistamine, dexamethasone) for step-up; Maintenance: 0.4mg/kg weekly or 0.8mg/kg every 2 weeks","Weekly or every-2-week SQ injections depending on dose; Monitor for CRS, infections, cytopenias, skin/nail changes (90% of patients), dysgeusia/loss of taste; IVIG replacement if hypogammaglobulinemia; CBC monitoring; Skin care management; Nutritional support for taste changes; Long-term monitoring",Step-up week 1, then weekly or biweekly,"Medicare Part B, Commercial insurance, Specialty pharmacy",Yes - Janssen CarePath Copay Program,Yes - Talvey REMS program,Yes - specialty pharmacy and certified sites,Inpatient step-up, then outpatient SQ injections
Vyndaqel,tafamidis meglumine,Pfizer,0069-0222-30,Cardiology,Transthyretin Amyloid Cardiomyopathy,Oral daily capsule (4 capsules),"$225,000/year","$135,000/year (340B)","Varies, typically $200,000-225,000/year",Yes - Pfizer Patient Assistance,Yes - Prior Authorization required,"Pre-treatment: ATTR-CM diagnosis confirmation, echocardiogram, functional assessment, NT-proBNP; Genotype testing if hereditary ATTR suspected","Not applicable - oral TTR stabilizer; 20mg capsules, 4 capsules = 80mg daily dose; Pfizer manufactured; Specialty pharmacy distribution","Dosing: 80mg once daily (four 20mg capsules taken together); Same time each day; With or without food; No dose adjustments needed for organ dysfunction; Continue indefinitely","Ongoing monitoring: Echocardiograms every 6-12 months, NT-proBNP monitoring every 3-6 months, 6-minute walk test, functional class assessment; Monitor disease progression; Well-tolerated therapy; Regular cardiology follow-up",Can start within 1-2 weeks of diagnosis confirmation,"Medicare Part D, Commercial insurance, Specialty cardiology programs",Yes - Pfizer Savings Program (can reduce to $0 copay),No REMS,Yes - specialty pharmacy,Oral medication at home
Vyndamax,tafamidis,Pfizer,0069-0232-30,Cardiology,Transthyretin Amyloid Cardiomyopathy,Oral daily capsule (1 capsule),"$225,000/year","$135,000/year (340B)","Varies, typically $200,000-225,000/year",Yes - Pfizer Patient Assistance,Yes - Prior Authorization required,"Pre-treatment: ATTR-CM diagnosis confirmation (biopsy, imaging, genetics), echocardiogram, functional status, biomarkers; Confirm diagnosis before initiating therapy","Not applicable - oral TTR stabilizer; Single 61mg capsule (free acid form, therapeutically equivalent to 80mg tafamidis meglumine); Specialty pharmacy","Dosing: 61mg once daily (one capsule); Preferred over Vyndaqel for patient convenience (1 vs 4 capsules); Same time daily; With or without food; No dose adjustments; Continue indefinitely","Ongoing monitoring: Echocardiograms every 6-12 months, NT-proBNP every 3-6 months, 6-minute walk test, NYHA class; Assess for disease stabilization or slowing of progression; Annual comprehensive cardiac evaluation",Can start within 1-2 weeks of diagnosis confirmation,"Medicare Part D, Commercial insurance, Specialty pharmacy",Yes - Pfizer Savings Program,No REMS,Yes - specialty pharmacy required,Oral medication at home
Sotatercept,sotatercept-csrk,Merck,0006-3070-01,Cardiology,Pulmonary Arterial Hypertension,Subcutaneous injection every 3 weeks,"$240,000/year","$144,000/year (340B)","Varies, typically $216,000-240,000/year",Yes - Merck Patient Assistance,Yes - Prior Authorization required,"Pre-treatment: PAH diagnosis confirmation (right heart catheterization), baseline 6-minute walk distance, echocardiogram, NT-proBNP, complete blood count (monitor hemoglobin/platelets), must be on stable PAH therapy","Not applicable - activin signaling inhibitor (fusion protein); Merck manufactured; Requires refrigeration; Pre-filled syringe; Specialty pharmacy distribution","Starting dose: 0.3mg/kg SQ every 3 weeks x 4 doses; Titrate to 0.7mg/kg if tolerated; Pre-filled syringe, subcutaneous injection (abdomen, thigh, or upper arm); Can be self-administered or caregiver after training; Rotate injection sites","Injections every 3 weeks ongoing; Monitor hemoglobin and platelets before each dose (can increase both); Monitor for bleeding if platelets elevated; 6-minute walk test every 3-6 months; Echocardiogram every 6 months; NT-proBNP; PAH clinic follow-up regularly; Right heart catheterization periodically",Can start within 1-2 weeks of screening,"Medicare Part B or Part D depending on administration, Commercial insurance",Yes - Merck Copay Assistance,No REMS,Yes - specialty pharmacy,Outpatient SQ injection (clinic or home)
Gilenya,fingolimod,Novartis,0078-0639-51,Multiple Sclerosis,Relapsing MS,Oral daily capsule,"$95,000/year","$57,000/year (340B)","Varies, typically $85,000-95,000/year",Yes - Novartis Patient Assistance,Yes - Prior Authorization required,"Pre-treatment: Cardiac evaluation (ECG, assess for heart block or bradycardia), ophthalmic exam (macular edema screening), complete blood count, liver function tests, varicella immunity (if not immune, vaccinate and wait 1 month), recent cardiovascular events are contraindications","Not applicable - oral sphingosine-1-phosphate receptor modulator; Novartis manufactured; Widely available through specialty pharmacy","First dose: 0.5mg once daily; First-dose observation required: ECG at baseline, then monitor heart rate/blood pressure hourly x 6 hours (cardiac effects most common in first 6 hours); If heart rate drops significantly or patient has risk factors, extend monitoring; Subsequent doses: 0.5mg daily at home","Continue 0.5mg daily; Monitor: Complete blood count every 3 months first year, then periodically; Liver enzymes periodically; Ophthalmic exam at 3-4 months then as needed for macular edema; MRI annually; Dermatologic exams for skin cancer; PML surveillance; Live vaccines contraindicated",Requires 6-hour first dose observation, then daily at home,"Medicare Part D, Commercial insurance, Specialty pharmacy",Yes - Novartis Copay Program,No REMS but first-dose monitoring required,Yes - specialty pharmacy,Oral at home after first dose observation
Vumerity,diroximel fumarate,Biogen,59075-0790-30,Multiple Sclerosis,Relapsing MS,Oral twice daily capsule,"$95,000/year","$57,000/year (340B)","Varies, typically $85,000-95,000/year",Yes - Biogen Support Services,Yes - Prior Authorization typically required,"Pre-treatment: Baseline complete blood count with differential, liver function tests; Assess for history of GI issues (GI side effects common); No specific cardiac or ophthalmologic screening required unlike some other MS therapies","Not applicable - oral fumarate (prodrug of monomethyl fumarate); Biogen manufactured; Available through specialty pharmacy; GI-optimized formulation compared to older fumarates","Dosing: 231mg twice daily; Take with or without food; GI side effects (flushing, nausea, diarrhea) common initially but often improve over time; Can take with food or aspirin to reduce flushing; No dose titration or first-dose observation required","Continue 231mg twice daily; Monitor: Complete blood count every 3-6 months (watch for lymphopenia); Liver function tests periodically; If lymphocyte count drops significantly (<500), consider interruption; MRI annually; Generally well-tolerated; No specific infection monitoring beyond lymphocyte counts",Can start immediately after baseline labs,"Medicare Part D, Commercial insurance, Specialty pharmacy",Yes - Biogen Copay Program,No REMS,Yes - specialty pharmacy dispenses,Oral medication at home
Rituxan,rituximab,Genentech/Roche,50242-0051-21,Multiple Sclerosis (off-label) / Oncology,MS (off-label), NHL, CLL,IV infusion - dosing varies by indication,"$30,000-60,000/year depending on dosing","$18,000-36,000/year (340B)","Varies by indication and dosing",Yes - Genentech Patient Foundation,Yes - Prior Authorization required,"Pre-treatment: Hepatitis B screening (risk of reactivation), baseline immunoglobulin levels, complete blood count; Assess for active infections; Patient education on infusion reactions and PML risk","Not applicable - monoclonal antibody targeting CD20; Widely available; Standard infusion product","Pre-medication with acetaminophen and antihistamine; Methylprednisolone often given; Infusion over 4-6 hours for first dose, faster for subsequent if tolerated; Monitor closely for infusion reactions (most common with first infusion); For MS (off-label): Various protocols, commonly 1000mg x 2 doses then 500-1000mg every 6-12 months","Ongoing monitoring: Complete blood count, immunoglobulin levels every 3-6 months; Monitor for infections (hypogammaglobulinemia common); PML surveillance - any new neuro symptoms need urgent workup; Infusion reactions less common with subsequent doses; Live vaccines contraindicated","Varies by indication - MS typically every 6-12 months","Medicare Part B, Commercial insurance, Specialty infusion",Yes - Genentech Copay Card for eligible patients,No REMS but Risk Evaluation,Yes - specialty infusion pharmacy,Outpatient infusion center
Briumvi,ublituximab,TG Therapeutics,72888-0101-01,Multiple Sclerosis,Relapsing MS,"IV infusion, initial course then every 24 weeks","$65,000/year","$39,000/year (340B)","Varies, typically $58,000-65,000/year",Yes - TG Therapeutics Patient Support,Yes - Prior Authorization required,"Pre-treatment: Hepatitis B screening, immunoglobulin levels, complete blood count, active infection screening; Patient education on infusion reactions and B-cell depletion effects","Not applicable - monoclonal antibody targeting CD20; Manufactured by TG Therapeutics; Specialty infusion distribution","Initial course: 150mg IV (given as 2 separate infusions of 150mg each, 2 weeks apart); Pre-medicate with antihistamine, antipyretic, and corticosteroid; Infusion over 4 hours first dose, can shorten to 1 hour if tolerated; Maintenance: 450mg IV every 24 weeks (every 6 months)","Maintenance infusions every 6 months (450mg); Monitor: Immunoglobulin levels, complete blood count every 6 months; Hepatitis B monitoring if risk factors; Infection surveillance; PML monitoring; Infusion reactions less common after first dose; Generally well-tolerated",Initial 2-week course, then every 6 months,"Medicare Part B, Commercial insurance, Specialty infusion",Yes - TG Therapeutics Copay Assistance,No REMS but monitoring required,Yes - specialty infusion centers,Outpatient infusion
Ponvory,ponesimod,Janssen,57894-0350-30,Multiple Sclerosis,Relapsing MS,Oral daily tablet with dose escalation,"$98,000/year","$58,800/year (340B)","Varies, typically $85,000-98,000/year",Yes - Janssen CarePath,Yes - Prior Authorization required,"Pre-treatment: Cardiac assessment (ECG, bradycardia or heart block evaluation), ophthalmic exam, complete blood count, liver function tests, hepatitis screening, varicella immunity; Recent cardiovascular events contraindicated","Not applicable - oral sphingosine-1-phosphate receptor modulator; Janssen manufactured; Starter pack with dose escalation; Specialty pharmacy","Dose escalation (starter pack): Day 1-2: 2mg, Day 3-4: 3mg, Day 5-6: 4mg, Day 7: 5mg, Day 8+: 10mg, Day 9+: 14mg, Day 10+: 20mg (maintenance); Escalation reduces cardiac effects; First-dose cardiac monitoring NOT required (unlike fingolimod); Take once daily with or without food","Maintenance: 20mg once daily continuously; Monitor: Complete blood count every 3 months first year; Liver enzymes periodically; Ophthalmic exam at 3-4 months then as needed (macular edema); Dermatologic exams (skin cancer); MRI annually; Infection monitoring; Live vaccines contraindicated",Can start within 1-2 weeks after screening,"Medicare Part D, Commercial insurance, Specialty pharmacy",Yes - Janssen CarePath Savings,No REMS,Yes - specialty pharmacy,Oral at home (no first-dose observation)
Tecfidera,dimethyl fumarate,Biogen,59075-0700-30,Multiple Sclerosis,Relapsing MS,Oral twice daily capsule,"$95,000/year","$57,000/year (340B)","Varies, typically $85,000-95,000/year",Yes - Biogen Support Services,Yes - Prior Authorization usually required,"Pre-treatment: Baseline complete blood count with differential, liver function tests; Counsel on GI side effects (flushing, abdominal pain, diarrhea) which are common initially; No cardiac or ophthalmic screening required","Not applicable - oral fumarate; Biogen manufactured; Specialty pharmacy distribution; Delayed-release capsules","Starting dose: 120mg twice daily x 7 days; Maintenance: 240mg twice daily starting day 8; Take with food to reduce GI effects; Flushing common initially (can pre-treat with aspirin); GI side effects often improve after first month; Capsules should be swallowed whole","Continue 240mg twice daily; Monitor: Complete blood count every 3-6 months (lymphopenia monitoring - hold if <500); Liver enzymes periodically; MRI annually; PML surveillance especially if lymphopenic; Generally well-tolerated after initial GI adjustment period",Can start immediately after baseline labs,"Medicare Part D, Commercial insurance, Specialty pharmacy",Yes - Biogen Copay Program,No REMS,Yes - specialty pharmacy,Oral medication at home
Enspryng,satralizumab,Genentech/Roche,50242-0160-01,Neuromyelitis Optica,NMO Spectrum Disorder (AQP4+),Subcutaneous injection,"$270,000/year","$162,000/year (340B)","Varies, typically $245,000-270,000/year",Yes - Genentech Patient Foundation,Yes - Prior Authorization required,"Pre-treatment: NMO/NMOSD diagnosis confirmation, AQP4 antibody testing (approved for AQP4+ but used in some AQP4- patients), tuberculosis screening, hepatitis B screening, vaccination status review; Baseline immunoglobulin levels, complete blood count","Not applicable - monoclonal antibody targeting IL-6 receptor; Genentech manufactured; Pre-filled pen for self-administration; Refrigeration required","Loading dose: 120mg SQ at Weeks 0, 2, and 4 (three doses over first month); Maintenance: 120mg SQ every 4 weeks starting Week 8; Self-administered with pre-filled pen (similar to insulin pen); Can inject in abdomen, thigh, or upper arm; Rotate injection sites","Monthly subcutaneous injections ongoing; Monitor: Complete blood count every 3 months (neutropenia risk); Liver enzymes periodically; Lipid panel periodically; Assess for infections; NMO relapse monitoring; MRI brain and spine periodically (frequency varies); Generally well-tolerated with injection site reactions being most common side effect",Loading over 4 weeks, then monthly ongoing,"Medicare Part B or Part D, Commercial insurance, Specialty pharmacy",Yes - Genentech Copay Card,No REMS,Yes - specialty pharmacy dispenses,Self-administered SQ at home
CAP-1002,allogeneic cardiosphere-derived cells,Capricor Therapeutics,N/A - Investigational,Cardiology (Investigational),Duchenne Muscular Dystrophy Cardiomyopathy,"Investigational - IV infusions, dosing varies by trial protocol","Investigational - pricing TBD","N/A - investigational","N/A - investigational",Patient assistance through clinical trials,Clinical trial enrollment,"Clinical trial screening: Duchenne muscular dystrophy diagnosis, cardiac function assessment (echo, MRI), trial eligibility criteria; Informed consent process; Baseline cardiac testing, functional assessments","Not applicable - allogeneic (off-the-shelf) cardiosphere-derived cells manufactured by Capricor; Cryopreserved product thawed prior to administration; Investigational cell therapy","Investigational protocol: Typically intracoronary infusion of cardiosphere-derived cells via cardiac catheterization; Dose and schedule vary by trial; Procedure performed in cardiac catheterization lab; Post-procedure monitoring for complications","Clinical trial follow-up: Regular cardiac imaging (echo, MRI) per protocol; Functional assessments; Safety monitoring; Long-term follow-up for cardiac function and adverse events; Trial-specific visit schedule",Per clinical trial protocol,Clinical trial coverage only,Clinical trial participation,No - investigational,Clinical trial sites only,Inpatient cardiac catheterization procedure
VX-880,stem cell-derived islet therapy,Vertex Pharmaceuticals,N/A - Investigational,Cell Therapy (Investigational),Type 1 Diabetes,"Investigational - single infusion, dosing varies by trial","Investigational - pricing TBD","N/A - investigational","N/A - investigational",Clinical trial patient support,Clinical trial enrollment,"Screening: Type 1 diabetes with hypoglycemia unawareness or severe glycemic lability, C-peptide negative, trial eligibility; Immune evaluation; Baseline metabolic testing; Informed consent","Manufacturing: Stem cell-derived pancreatic islet cells; Differentiation from pluripotent stem cells; Quality testing; Investigational product","Investigational: Portal vein infusion of islet cells similar to cadaveric islet transplantation; Performed interventional radiology or surgery; Immunosuppression initiated (tacrolimus, sirolimus, or other protocol-specific); Post-procedure monitoring","Clinical trial follow-up: Frequent glucose monitoring, C-peptide measurements, insulin requirements tracking; Immunosuppression monitoring (drug levels, renal function, infections); Long-term islet function assessment; Regular trial visits",Per clinical trial protocol,Clinical trial only,Trial participation support,No - investigational,Clinical trial sites,Inpatient procedure with recovery
CTX110,allogeneic CRISPR-edited CAR-T,CRISPR Therapeutics/Vertex,N/A - Investigational,CAR-T (Investigational),CD19+ B-Cell Malignancies,"Investigational - single infusion, patient does not require leukapheresis","Investigational - pricing TBD","N/A - investigational","N/A - investigational",Clinical trial support,Trial enrollment,"Trial screening: CD19+ malignancy, prior therapy requirements, organ function, performance status; Bridging therapy planning; No leukapheresis required (off-the-shelf product); Informed consent","Manufacturing: Allogeneic (donor) T-cells edited with CRISPR/Cas9 to remove TCR (prevent GVHD) and PD-1 (enhance function), transduced with CD19 CAR; Off-the-shelf product - no patient-specific manufacturing wait","Investigational: Lymphodepletion per protocol; CTX110 infusion (dose per trial); Hospitalization for CRS/neurotoxicity monitoring per CAR-T standards; Tocilizumab/steroids available; Monitoring similar to autologous CAR-T","Clinical trial monitoring: CRS/ICANS per CAR-T protocols; GVHD monitoring (allogeneic product); Persistence of allogeneic cells; Anti-drug antibodies; Efficacy assessments; Long-term follow-up per trial",Per clinical trial timeline,Clinical trial coverage,Trial support programs,Clinical trial oversight,Trial sites only,Inpatient per trial protocol
PBCAR0191,allogeneic CAR-T,Precision BioSciences,N/A - Investigational,CAR-T (Investigational),CD19+ B-Cell Malignancies,"Investigational - off-the-shelf CAR-T, no patient leukapheresis","Investigational - pricing TBD","N/A - investigational","N/A - investigational",Clinical trial support,Trial enrollment required,"Trial screening: B-cell malignancy diagnosis, eligibility criteria, organ function, prior therapies; Bridging therapy if needed; No leukapheresis - off-the-shelf product; Informed consent","Manufacturing: Allogeneic CAR-T cells edited with ARCUS platform to delete TCR genes (prevent GVHD), insert CD19 CAR; Off-the-shelf product shipped to site as needed","Investigational: Lymphodepletion chemotherapy per protocol; PBCAR0191 infusion (dose per trial); Hospitalization minimum 7 days for CRS/neurotoxicity monitoring per CAR-T standards; Standard CAR-T toxicity management","Trial follow-up: CRS/ICANS monitoring; GVHD surveillance (allogeneic T-cells); Persistence and efficacy assessments; Safety monitoring; Disease response evaluation per trial schedule; Long-term follow-up",Per trial protocol,Clinical trial,Trial participation support,Clinical trial,Trial sites only,Inpatient hospitalization per trial
UB-VV111,in vivo CAR-T,Umoja Biopharma,N/A - Investigational,CAR-T (Investigational),PSMA+ Prostate Cancer,"Investigational - single IV dose, no leukapheresis or ex vivo manufacturing","Investigational - pricing TBD","N/A - investigational","N/A - investigational",Clinical trial support,Trial enrollment,"Screening: PSMA+ metastatic castration-resistant prostate cancer, trial eligibility, organ function, performance status; No leukapheresis needed (in vivo approach); Informed consent; Baseline imaging","Manufacturing: Lentiviral vector targeting T-cells in vivo; Manufactured and shipped to site; No patient-specific manufacturing; Investigational in vivo CAR-T platform","Investigational: Pre-medication per protocol; UB-VV111 IV infusion (lentiviral vector transduces T-cells in vivo to express PSMA-targeted CAR); Monitoring for CRS/neurotoxicity though potentially different kinetics than ex vivo CAR-T; Hospitalization per protocol","Trial monitoring: CRS/toxicity monitoring; T-cell transduction efficiency assessment; CAR-T expansion in vivo; PSA and imaging response; Safety follow-up; Long-term persistence and efficacy; Per trial schedule",Per trial protocol,Clinical trial coverage,Trial support,Clinical trial oversight,Trial sites,Inpatient/outpatient per trial
NTLA-2001,in vivo CRISPR therapy,Intellia Therapeutics,N/A - Investigational,Gene Editing (Investigational),ATTR Amyloidosis,"Investigational - single IV infusion, one-time treatment","Investigational - pricing TBD if approved","N/A - investigational","N/A - investigational",Clinical trial support,Trial enrollment,"Screening: ATTR amyloidosis diagnosis (hereditary), genotype confirmation, organ function assessment, cardiac/neurologic evaluation; Trial eligibility; Informed consent; Baseline TTR levels","Not applicable - NTLA-2001 is lipid nanoparticle delivering CRISPR/Cas9 system targeting TTR gene in liver; Single infusion product; In vivo gene editing approach","Investigational: Single IV infusion of NTLA-2001; CRISPR/Cas9 delivered to hepatocytes via LNP; Edits TTR gene to knock out production; Monitoring post-infusion; Typically outpatient with observation; Dose escalation trials completed","Trial follow-up: TTR protein levels (goal: sustained reduction 80-90%); Cardiac assessments (echo, biomarkers); Neurologic assessments; Quality of life; Safety monitoring including off-target editing evaluation; Long-term follow-up for durability",Single infusion, long-term follow-up,Clinical trial,Trial support,Clinical trial,Trial sites only,Outpatient infusion with observation
EDIT-101,in vivo CRISPR therapy,Editas Medicine/Allergan,N/A - Investigational,Gene Editing (Investigational),Leber Congenital Amaurosis 10 (LCA10),"Investigational - single subretinal injection, one eye at a time","Investigational - pricing TBD","N/A - investigational","N/A - investigational",Clinical trial support,Trial enrollment,"Screening: LCA10 diagnosis with CEP290 mutation, retinal function assessment, visual fields, sufficient viable retinal cells; Ophthalmologic evaluation; Trial eligibility; Informed consent; Baseline vision testing","Not applicable - EDIT-101 is AAV vector delivering CRISPR/Cas9 system targeting CEP290 IVS26 mutation in retinal cells; Subretinal injection product","Investigational: Subretinal injection under general anesthesia (vitrectomy approach); CRISPR editing occurs in vivo in retinal cells; One eye treated initially; Immunosuppression per protocol (typically corticosteroids); Second eye treatment after safety evaluation","Trial follow-up: Visual function testing (visual acuity, visual fields, mobility testing); Retinal imaging; Safety monitoring; Immune response assessment; Durability of vision improvement; Long-term follow-up per protocol; Second eye treatment interval per trial",Per trial protocol with staged eye treatment,Clinical trial,Trial support,Clinical trial,Trial sites only,Outpatient surgical procedure